Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $164,070 | $1,189 | $0 | $0 |
| % Growth | 13,699% | – | – | – |
| Cost of Goods Sold | $123,995 | $10,755 | $0 | $0 |
| Gross Profit | $40,075 | -$9,566 | $0 | $0 |
| % Margin | 24.4% | -804.5% | – | – |
| R&D Expenses | $282,336 | $344,077 | $294,781 | $259,039 |
| G&A Expenses | $0 | $0 | $104,097 | $83,664 |
| SG&A Expenses | $153,017 | $106,916 | $104,097 | $83,664 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $435,353 | $450,993 | $398,878 | $342,703 |
| Operating Income | -$395,278 | -$460,559 | -$398,878 | -$342,703 |
| % Margin | -240.9% | -38,735% | – | – |
| Other Income/Exp. Net | $20,273 | $13,043 | $2,985 | $451 |
| Pre-Tax Income | -$375,005 | -$447,516 | -$395,893 | -$342,252 |
| Tax Expense | -$2,828 | -$3,479 | $0 | $0 |
| Net Income | -$372,177 | -$444,037 | -$395,893 | -$342,252 |
| % Margin | -226.8% | -37,345.4% | – | – |
| EPS | -1.28 | -1.89 | -2.49 | -2.23 |
| % Growth | 32.3% | 24.1% | -11.7% | – |
| EPS Diluted | -1.28 | -1.89 | -2.49 | -2.23 |
| Weighted Avg Shares Out | 289,877 | 235,131 | 159,259 | 153,406 |
| Weighted Avg Shares Out Dil | 289,877 | 235,131 | 159,259 | 153,406 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20,273 | $13,043 | $2,985 | $451 |
| Interest Expense | $0 | $0 | $2,985 | $0 |
| Depreciation & Amortization | $43,606 | $33,127 | $21,135 | $13,980 |
| EBITDA | -$351,672 | -$427,432 | -$377,743 | -$328,723 |
| % Margin | -214.3% | -35,948.9% | – | – |